Reported 3 days ago
The nomination of Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services has created uncertainty in the healthcare sector, particularly affecting vaccine stocks. Analysts express concern over Kennedy's controversial anti-vaccine stance and views on obesity treatments, suggesting he could influence key regulations related to vaccines and obesity drugs. His potential policies on food regulation and drug pricing are also under scrutiny as Wall Street waits to see how his leadership might unfold.
Source: YAHOO